Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

by · The Cerbat Gem

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 27,645 shares, a growth of 172,681.2% from the August 15th total of 16 shares. Based on an average daily volume of 474,592 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Oncotelic Therapeutics Stock Performance

Shares of OTLC traded down $0.00 during mid-day trading on Thursday, hitting $0.03. 268,000 shares of the company’s stock were exchanged, compared to its average volume of 274,358. Oncotelic Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.11. The business’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.04. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $13.69 million, a P/E ratio of 0.05 and a beta of -0.24.

Oncotelic Therapeutics Company Profile

(Get Free Report)

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.

See Also